As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...

plus a U.K. headquarters for the German biopharma in London, which will also house an artificial intelligence “hub” led by BioNTech’s AI subsidiary InstaDeep. As part of the commitment ...

Ivonescimab was cleared in China last month and is in several other late-stage studies. BioNTech has a PD-1/VEGF prospect also acquired from China that’s currently in Phase 3 testing. By comparison, ...

Lindsay Matinas and Keerstyn Tabor from Dallas High School; Rebekah Klinetop from Hazleton Area Academy of Sciences; Camilla Treat, Homeschool; Jake Grzech from Pittston Area and Aaron Girvan from ...

Independent Director at Matinas BioPharma Holdings, Inc. (starting in 2025), and Executive Advisor at Methuselah Capital Management LLC. Former jobs include Vice Chairman at Alliance for ...

Mr. Neugeboren is currently an Independent Director at Matinas BioPharma Holdings, Inc., starting in 2025. Mr. Neugeboren is currently the Chief Strategy Officer at Cronus Pharma LLC, starting in ...

Citing new information from British drugmaker GSK, U.S. lawmakers are pushing forward with a probe into a pandemic-era political controversy centered around the timing of trial results for Pfizer ...